Robbins Farley’s Ginkgo Bioworks DNA Stock Holding History

Robbins Farley’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40	Closed	-$450	–	179
2025 Q2	$450	Buy	+40	New	+$310	﹤0.01%	153

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Robbins Farley's DNA Position: Q3 2025 in Review

Robbins Farley sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 40 shares — an estimated $450 sold.

Robbins Farley first reported a position in DNA in Q2 2025 and held it in 1 quarter. The position peaked at $450 in Q2 2025. 173 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

Robbins Farley reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
Robbins Farley sold 40 Ginkgo Bioworks shares in Q3 2025, an estimated $450.
Robbins Farley first reported a position in Ginkgo Bioworks in Q2 2025 and held it in 1 quarter.
Robbins Farley's Ginkgo Bioworks position peaked at $450 in Q2 2025.
173 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on Robbins Farley's 13F filing for Q3 2025, filed 15 Oct 2025.